News Chart Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 20:58:51 02/09/2026 BST			5-day change	1st Jan Change
14.24 ^USD	-0.45%		-0.63%	-8.86%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

fc05cf80c96b1dc.bjDh8BOAHfLgUbwWQ3eU4lMN0KRthvLGvRqMCt57wR8.XkTSqCHpVrXQIc5Bbg6toGo_tMsp8rS1znX0f5sJm08_XoqYe-RWwpMTjA~308914a47fc4d081fa542b3cdafbc3eb